Microbial fermentation has been used by humans for thousands of years to produce bread, beer, wine, and fermented foods. In the modern context, industrial microbial fermentation harnesses engineered or selected microorganisms to produce pharmaceuticals, enzymes, chemicals, fuels, and food ingredients at commercial scale. The global industrial fermentation market encompasses products worth hundreds of billions of dollars, from insulin and antibiotics to citric acid and amino acids, making it one of the most economically significant applications of biotechnology.
The choice of microbial host profoundly influences fermentation performance. Escherichia coli and Saccharomyces cerevisiae are the most widely used production organisms due to their well-understood genetics and established fermentation protocols. Corynebacterium glutamicum dominates amino acid production, while filamentous fungi like Aspergillus niger are preferred for organic acid and enzyme manufacturing. Companies like Ginkgo Bioworks engineer diverse microbial hosts across their biofoundry platform, optimizing strains for specific products and fermentation conditions to maximize productivity and economics.
Advances in synthetic biology are expanding what microbial fermentation can produce. Engineered microbes can now synthesize complex molecules previously accessible only through chemical synthesis or extraction from natural sources, including terpenoids, alkaloids, and non-natural amino acids. Amyris demonstrated the commercial viability of this approach with its farnesene platform, producing a sesquiterpene used in fragrances, lubricants, and fuels. The integration of biosensors, dynamic pathway regulation, and adaptive laboratory evolution with traditional fermentation optimization is pushing the boundaries of what can be manufactured biologically.